Key to treating cancer - keep it in dormancy and thereby avoid metastases via drug named fostamatinib (Tavalisse)

[Part 1 of 2]

https://medicalxpress.com/news/2019-04-lock-n-block-drug-cancer-metastasizing.html

'Lock-'n'-block' drug may prevent cancer from metastasizing

by Steve Tally

April 26, 2019

"They got all of it" are the reassuring words people hope to hear following cancer surgery, but a growing understanding of the science of how cancer spreads, and metastasizes, is suggesting that not only is this almost never true but—and here is the surprising part—it might be better to try to contain the cancer than to eliminate it.

The new approach, which at this point has been tested only in animal models, is called "lock-'n' -block," and a national team of scientists led by researchers at Purdue University has found that a drug already on the market for another use is showing strong promise as a therapy to keep breast cancer from metastasizing.

Michael Wendt, assistant professor of medicinal chemistry and molecular pharmacology, says that cancer researchers are beginning to realize they have been chasing an impossible goal.

"Most cancer therapy is targeted with the idea that we want to kill all of the cancer cells. Rid the body of cancer. But recently, there are lots of studies that suggest that we're never going to be able to do that. Cancer cells evolve so fast that they will always find a way to overcome any type of therapy," Wendt said. "An emerging concept in cancer treatment is that maybe we shouldn't try to kill all of the cancer cells, but try to keep them in a low state that doesn't generate any kind of symptoms. A sort of dormancy, if you will."

Wendt has led a multi-institutional study that has identified a drug —fostamatinib, which is sold under the trade name Tavalisse—that was shown to be effective in mice in blocking and containing metastatic cancer cells. The research was recently published in the journal Cancer Research.

Aparna Shinde, a researcher at AbbVie Inc., and formerly a graduate student in the Purdue's Department of Medicinal Chemistry and Molecular Pharmacology, said the research focused on breast cancer because it is especially known to lead to metatisizing cancers years later.

"After you have breast cancer you always get this dissemination of cancer cells," she said. "Breast cancer is no longer considered a curable disease—it is now considered a chronic disease, because 10 or 20 years later, you can get secondary tumors because of the metastasizing cells.

"But now we have shown that we can block these cells in a dormant state so that even if a patient has these metastizing cells we can hold them in this state for a very long time."

Wendt explains that when cancer cells move from a primary tumor and go to another part of the body, they can go through some form of years-long dormancy or latency. These cancer cells are very resistant to current drug therapies, because current drugs are designed to target cells that grow faster than normal cells, as tumor cells do. That is not true of these disseminated cancer cells, which can lie dormant for many, many years.

"So that's the goal we are exploring now. Instead of trying to eliminate those disseminated cells, how do we keep them in that dormant state?" Wendt said.

The researchers used the drug fostamatinib because it inhibits a particular protein, spleen tyrosine kinase (SYK), that is found in these disseminated cancer cells.

[Part 1 of 2]

>>6344573

[Part 2 of 2]

"This is great for us because this is a drug with low toxicity. It's designed for people with chronic disease so that they can take for a long time," Wendt said. "So, we think fostamatinib is a perfect candidate for this kind of years-long 'lock-'n'-block' type of approach. We think this is a good candidate to move forward for a trial to see if we can stabilize dormancy. If SYK is expressed in other cancers this could apply to those as well."

In their current study, the researchers removed breast cancer tumors from the mice surgically. The tumor cells were labeled with luciferase, the bioluminescent firefly protein, which allows the researchers to track and quantify the level of metatisizing cells.

The researchers found that the cancer cells treated with fostamatinib remained in a dormant state and did not cause metastases in other areas of the body.

"Our work is unique because there hasn't been much research that tests treatments in a post-surgical metastatic setting. Most research is focused on treating the primary tumor. We are looking to target the later processes of disease—to see if we can hold tumor cells in their dormant state," Wendt said. "But you can imagine that clinical trials for this kind of thing is going to be very difficult because technically the patients are in remission and disease-free. We suspect that these patients have these dormant cancer cells disseminating through their bodies, but we don't have a way to detect those right now."

Journal article at:

Aparna Shinde et al. Spleen Tyrosine Kinase–Mediated Autophagy Is Required for Epithelial–Mesenchymal Plasticity and Metastasis in Breast Cancer, Cancer Research (2019).

DOI: 10.1158/0008-5472.CAN-18-2636

http://cancerres.aacrjournals.org/content/79/8/1831

Anti-cancer drug Libtayo now available for EU squamous cell carcinoa patients; already approved in US and Canada

https://medicalxpress.com/news/2019-04-eu-anti-skin-cancer-drug.html

In first for EU, anti-skin cancer drug approved

April 26, 2019

French pharmaceutical giant Sanofi on Friday said the European Medicines Agency had conditionally approved its anti-cancer drug Libtayo, the first drug of its kind to be authorised for use in the EU.

The tumour-reducing drug is aimed at patients with the second most common form of skin cancer—cutaneous squamous cell carcinoma (CSCC)—whose cancer is advanced, and who are not candidates for surgery or radiation therapy.

Confirming the conditional approval, the agency added in a statement that it had "adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Libtayo, intended for the treatment of advanced cutaneous squamous cell carcinoma".

"The benefits with Libtayo are its ability to reduce tumour size and to prevent progression of the tumour for longer," it said.

No drugs for the treatment of CSCC are currently approved in the EU, according to Sanofi.

Final approval of the drug will be given subject to Sanofi providing further results from clinical trials.

The US Food and Drug Administration (FDA) approved Libtayo in September 2018 while Health Canada gave it the conditional green light earlier this month.